All In Biotech

Drug Trial Radar · NCT02646748

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Pembrolizumab + INCB Combinations in Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Mar 31, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

159

Actual

Start

Jan 25, 2016

Primary completion

Nov 7, 2019

Study completion Nov 20, 2020

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Jan 6, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter, Phase 1b platform study in subjects with advanced or metastatic solid tumors (Part 1a) and subjects with selected solid tumors (Part 1b and Part 2). Two treatment groups (Group A and Group B) will be evaluated Part 1a utilizes a 3+3 design to evaluate pembrolizumab and INCB combinations in advanced solid tumors. Group A will evaluate a JAK inhibitor with JAK1 selectivity itacitinib (INCB039110) in combination with pembrolizumab (MK-3475) and Group B will evaluate a PI3K-delta inhibitor (INCB050465) in combination with pembrolizumab to determine the maximum tolerated dose (MTD) or PAD and recommend a dose for the Part 1b safety expansion with each combination. Once the recommended dose has been identified in Part 1a, subjects with select solid tumor types will be enrolled into safety expansion cohorts based upon prior treatment history with a PD-1 pathway-targeted agent (Part 1b) for each combination. Part 2 utilizes a Simon 2-Stage design to evaluate INCB050465 in combination with pembrolizumab in patients with small cell lung cancer (SCLC) and a 1 stage design to evaluate the combination in patients with non-small cell lung cancer (NSCLC) and urothelial cancer (UC).

Conditions

  • Colorectal Cancer (CRC)
  • Endometrial Cancer
  • Melanoma
  • Head and Neck Cancer
  • Lung Cancer
  • MMR-deficient Tumors
  • Breast Cancer
  • Pancreatic Cancer
  • Renal Cell Carcinoma (RCC)
  • Solid Tumors
  • UC (Urothelial Cancer)

Interventions

  • PembrolizumabDrug

    Pembrolizumab 200 mg IV Q3W.

  • itacitinibDrug

    Itacitinib tablets administered orally once daily.

  • INCB050465Drug

    INCB050465 tablets administered orally once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Evaluation of safety and tolerability as measured by the frequency, duration, and severity of adverse eventsTime frame: Duration of study treatment and up to 120 days after the last dose of study drug

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

  • John Wayne Cancer Institute at Providence Saint John's Health Center

    Santa Monica, California

  • Georgetown University Medical Center Lombardi CCC

    Washington D.C., District of Columbia

  • Hematology-Oncology Associates of Treasure Coast

    Port Saint Lucie, Florida

  • Emory University, Winship Cancer Institute

    Atlanta, Georgia

  • University of Kentucky, Markey Cancer Center

    Lexington, Kentucky

  • The Center for Cancer and Blood Disorders (RCCA MD LLC-Maryland Vidision)

    Bethesda, Maryland

  • Beth Israel Medical Deaconess Medical Center

    Boston, Massachusetts

  • Dana Farber Cancer institute

    Boston, Massachusetts

  • Karmanos Cancer Center

    Detroit, Michigan

  • Henry Ford Hospital System

    Detroit, Michigan

  • St. Luke's Hospital of Kansas City

    Kansas City, Missouri

  • NYU Laura & Isaac Perlmutter Cancer Center at NYU Langone

    New York, New York

  • Duke Cancer Institute

    Durham, North Carolina

  • UPMC CancerCenters, Hilman Cancer Center

    Pittsburgh, Pennsylvania

  • HOPE Cancer Center of East Texas

    Tyler, Texas

  • Utah Cancer Specialists

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.